Physician profile
Mark Anthony Williams
NPI 1710179585
$33,162.78
in general payments reported to CMS, 2019-2025
69 companies · $4,144 in 2025
The $4,144 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,396 · 2020: $3,840 · 2021: $5,102 · 2022: $5,682 · 2023: $4,812 · 2024: $3,186 · 2025: $4,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,142.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,447.46 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $2,512.02 | 2019-2025 | Otezla, Evenity, Repatha |
| Glaxosmithkline, LLC. | $2,051.83 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $1,832.69 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,652.67 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Janssen Pharmaceuticals, INC | $1,594.57 | 2019-2025 | Spravato |
| Novo Nordisk INC | $1,503.50 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Esperion Therapeutics, INC. | $1,351.76 | 2020-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $1,279.79 | 2019-2025 | Entresto, Leqvio |
| Amarin Pharma, INC. | $1,222.31 | 2019-2023 | |
| Pfizer INC. | $1,149.37 | 2019-2025 | |
| Bausch Health US, LLC | $1,026.93 | 2019-2025 | Wellbutrin, Aplenzin |
| Lilly USA, LLC | $947.96 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $691.45 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $650.81 | 2020-2023 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.